Core Viewpoint - Citigroup reports that China Biopharmaceutical (01177) has announced the acquisition of private biotech company Hygieia, specializing in small interfering RNA (siRNA) drugs, with a maximum base consideration of 1.2 billion RMB [1] Group 1: Acquisition Details - The acquisition is expected to enhance China Biopharmaceutical's innovation capabilities and licensing potential [1] - The deal solidifies the company's position as a leader among Chinese innovative pharmaceutical firms [1] Group 2: Hygieia's Contributions - Hygieia has developed several differentiated delivery platforms, with candidate drugs in its pipeline including Kylo-11, Kylo-12, Kylo-0603, HJY-10, and HJY-02 [1] - The acquisition will enable China Biopharmaceutical to establish a new generation of cardiovascular innovation pipeline [1] Group 3: Market Expansion - The deal strengthens the company's positioning in weight management and metabolic disease sectors [1] - It also expands into new frontiers in chronic disease management [1] Group 4: Financial Outlook - Citigroup sets a target price of HKD 10.8 and maintains a "Buy" rating for China Biopharmaceutical [1]

Core Viewpoint - Citigroup's report indicates that China Biologic Products (01177) has announced the acquisition of private biotech company Hygieia, which focuses on small interfering RNA (siRNA) drugs, with a maximum base consideration of 1.2 billion RMB [1] Group 1: Acquisition Details - The acquisition is expected to enhance China Biologic's innovation capabilities and licensing potential, solidifying its position as a leader among Chinese innovative pharmaceutical companies [1] - Hygieia has developed several differentiated delivery platforms, with a research pipeline that includes candidate drugs Kylo-11, Kylo-12, Kylo-0603, HJY-10, and HJY-02 [1] Group 2: Strategic Implications - Through this acquisition, China Biologic will establish a new generation of cardiovascular innovation pipeline, strengthening its presence in weight management and metabolic disease sectors [1] - The move also aims to expand into new frontiers in chronic disease management [1] Group 3: Market Outlook - Citigroup has set a target price of 10.8 HKD and maintains a "Buy" rating for China Biologic following this acquisition [1]

Company Overview - The company announced a 100% acquisition of Hejia Bio for a consideration of 1.2 billion yuan, which is adjustable [1] - The payment structure includes a mix of cash and equity, with 50% cash payment to founding shareholders on the closing date and the remaining 50% to be unlocked over 24 to 36 months [1] Industry Insights - Hejia Bio specializes in siRNA innovative drugs, focusing on three major chronic disease areas: weight management, cardiovascular, and neurological systems [1] - The core platform, MVIP, is the world's first clinically validated liver-targeted delivery platform capable of achieving long-lasting effects with annual injections [1] - The dual delivery technology addresses the industry challenge of achieving combined efficacy, while the neural targeting delivery platform aims for effective central and peripheral nervous system treatments [1] Strategic Implications - The acquisition is expected to enhance the company's capabilities in chronic disease management, addressing existing limitations in efficacy, safety, and patient compliance in current therapies [2] - The collaboration is anticipated to accelerate the clinical development and commercialization of Hejia Bio's products, leveraging the company's established R&D and sales channels [2] Financial Projections - The adjusted net profit forecasts for 2025 and 2026 remain at 4.47 billion yuan and 4.92 billion yuan, respectively, with an introduction of a 2027 adjusted net profit of 5.42 billion yuan [2] - The current stock price corresponds to adjusted P/E ratios of 23.8 and 21.0 for 2026 and 2027, respectively, with a target price of 8.90 HKD, indicating a potential upside of 28.8% [2]

Group 1 - The core viewpoint of the report is that China Biologic Products (01177) maintains a target price of HKD 8.9 and an "outperform" rating, with adjusted net profit forecasts for 2025 and 2026 remaining at RMB 4.47 billion and RMB 4.92 billion respectively, and a new forecast for 2027 introduced at RMB 5.42 billion [1] - The company announced a 100% acquisition of Hejia Bio for a consideration of RMB 1.2 billion, which focuses on the siRNA sector, particularly in the areas of metabolic diseases, cardiovascular diseases, and neurological disorders, with a core platform that has competitive advantages [1] - The report highlights that existing therapies in the chronic disease field generally have limitations in efficacy, safety risks, and low patient compliance, indicating a significant unmet clinical need [1] Group 2 - The acquisition is expected to help China Biologic Products build a next-generation cardiovascular treatment innovation pipeline and enhance its layout in the metabolic disease sector [1] - The company's established R&D system and sales channels are anticipated to facilitate the efficient clinical advancement and subsequent commercialization of Hejia Bio's products, leading to potential synergistic benefits for both parties [1]

Core Viewpoint - CICC maintains a target price of HKD 8.9 for China Biologic Products (01177) and a "outperform industry" rating, with adjusted net profit forecasts for 2025 and 2026 remaining at RMB 4.47 billion and RMB 4.92 billion respectively, and introducing a forecast of RMB 5.42 billion for 2027 [1] Group 1 - The company announced a 100% acquisition of Hejia Bio for RMB 1.2 billion [1] - Hejia Bio focuses on the siRNA sector, particularly in the areas of weight loss metabolism, cardiovascular, and neurological diseases, with a core platform that has competitive advantages [1] - The existing therapies in the chronic disease field generally have limitations in efficacy, safety risks, and low patient compliance, indicating a significant unmet clinical need [1] Group 2 - The acquisition is expected to help China Biologic Products build a next-generation cardiovascular treatment innovation pipeline and enhance its layout in the weight loss metabolism field [1] - The company's established R&D system and sales channels are likely to facilitate the efficient clinical advancement and subsequent commercialization of Hejia Bio's products, leading to potential synergistic benefits for both parties [1]

Core Viewpoint - China National Pharmaceutical Group (China Biopharmaceutical) announced a full acquisition of innovative drug company Hejiya Biopharmaceutical for 1.2 billion yuan, marking its second acquisition in a year [2][3] Group 1: Acquisition Details - The acquisition of Hejiya Biopharmaceutical is valued at 1.2 billion yuan, with a market-to-research ratio of 18.75 times based on Hejiya's projected R&D expenditure of approximately 64 million yuan for 2024 [5] - Hejiya Biopharmaceutical focuses on the development of small nucleic acid drugs, a hot area in innovative pharmaceuticals, with its lead clinical pipeline targeting lipoprotein(a) [4][5] - The acquisition aligns with China Biopharmaceutical's strategy to focus on major chronic diseases and oncology, as stated by the chairman, Xie Qirun [5] Group 2: Company Background and Financials - China Biopharmaceutical has a history of acquisitions, including a notable 950 million USD acquisition of Lixin Pharmaceutical in 2025, which set a record for traditional Chinese pharmaceutical companies acquiring innovative firms [3] - The company has significant cash reserves, with over 300 billion yuan in total assets, making it one of the most financially robust pharmaceutical companies in China [5] - Following the announcement of the acquisition, China Biopharmaceutical's stock price rose by 3.76%, reaching 7.17 HKD per share, with a total market capitalization of 134.5 billion HKD [6]

Group 1 - China Biopharmaceutical (01177) shares rose over 5%, currently up 4.92% at HKD 7.24, with a trading volume of HKD 303 million [1] - The company announced a full acquisition of Hejiya, with the deal set to close on January 13, 2026, for a maximum base price of RMB 12 million, payable in cash and shares [1] - Hejiya specializes in the research and development of small interfering RNA (siRNA) innovative drugs, focusing on chronic diseases such as metabolic disorders, cardiovascular diseases, and neurological conditions [1] Group 2 - Hejiya has developed a differentiated delivery platform with independent intellectual property rights, featuring the MVIP (Multi-Valent Import Platform), which is the first clinically validated liver-targeted delivery platform capable of "one injection per year" for long-lasting treatment [2] - This platform addresses adherence issues in chronic disease treatment, which is a significant challenge in the industry [2]

Core Viewpoint - China National Pharmaceutical Group announced the acquisition of domestic siRNA innovative drug company Hejia Bio for a total price of 1.2 billion RMB, marking a significant move in the small nucleic acid sector following its investment in Saintin Bio [1] Group 1: Company Overview - China National Pharmaceutical Group's stock rose over 4% in early trading, currently at 7.12 HKD with a trading volume of 134 million HKD [1] - Hejia Bio is a pioneering biopharmaceutical company focused on the research and development of small interfering RNA (siRNA) innovative drugs [1] Group 2: Strategic Importance - The acquisition of Hejia Bio represents a key strategic investment in the small nucleic acid space, following the previous investment in Saintin Bio [1] - Hejia Bio has developed an integrated drug development system from target discovery to proof of concept (POC), focusing on three major chronic disease areas: weight loss metabolism, cardiovascular and cerebrovascular, and nervous system [1] Group 3: Asset Portfolio - Hejia Bio possesses four clinical-stage assets and over ten preclinical assets, all of which have first-in-class and best-in-class potential [1]

Group 1 - The core point of the article is that China National Pharmaceutical Group (中生制药) experienced a significant increase in its stock price, rising over 4% in early trading and closing up by 3.04% at HKD 7.12 per share [1] - The trading volume for the stock reached HKD 134 million, indicating strong investor interest and activity in the market [1]

Group 1 - China Biopharmaceutical (01177) has seen its stock price increase by over 5%, currently trading at HKD 7.24 with a transaction volume of HKD 303 million [1] - The company announced a full acquisition of Hejia, with the deal set to close on January 13, 2026, for a maximum base price of RMB 12 million, which may be adjusted and paid partially in cash and partially in shares [1] - Upon completion of the acquisition, Hejia will become a wholly-owned subsidiary of China Biopharmaceutical [1] Group 2 - Hejia is a pioneering biopharmaceutical company focused on the research and development of small interfering RNA (siRNA) innovative drugs, with an integrated drug development system from target discovery to clinical proof of concept [2] - The strategic acquisition is expected to accelerate the group's innovation and clinical advancement in chronic disease areas, particularly in weight loss metabolism, cardiovascular, and neurological diseases [2] - Hejia has developed a differentiated delivery platform with independent intellectual property rights, including the MVIP (Multi-Valent Import Platform), which is the world's first clinically validated liver-targeted delivery platform capable of providing long-lasting treatment with "one injection per year" [2]